Oehen S, Ohashi P S, Aichele P, Bürki K, Hengartner H, Zinkernagel R M
Department of Pathology, University of Zurich, Switzerland.
Eur J Immunol. 1992 Dec;22(12):3149-53. doi: 10.1002/eji.1830221218.
Experiments with transgenic mice expressing the glycoprotein (GP) of lymphocytic choriomeningitis virus (LCMV) under the control of the rat insulin promoter (RIP) have demonstrated that potentially self-reactive T cells that normally ignore self peptides may nevertheless be induced by self peptides or "cross-reactive" foreign (e.g. viral) peptides that arise in the host in an immunogenic form; once activated these potentially self-reactive T cells may cause autoaggressive diseases (e.g. diabetes). The possibility of vaccinating against such T cell-mediated immunopathological diseases was evaluated in the RIP-GP transgenic mouse line Bln. Any attempt to vaccinate with the self antigen itself (e.g. recombinant vaccinia virus expressing LCMV-GP) failed to protect mice from disease. However, immunization with a recombinant vaccinia virus expressing LCMV-nucleoprotein (vacc-NP) as a non-GP LCMV vaccine was able to modulate the immune response and prevented autoaggressive disease in a MHC-dependent fashion. In contrast, tolerance induction neonatally or, more generally applicable, by lethal irradiation and reconstitution with neo-self antigen-expressing bone marrow cells always resulted in prevention of virally induced diabetes in this model situation.
对在大鼠胰岛素启动子(RIP)控制下表达淋巴细胞性脉络丛脑膜炎病毒(LCMV)糖蛋白(GP)的转基因小鼠进行的实验表明,通常忽略自身肽段的潜在自身反应性T细胞,仍可能被宿主中以免疫原性形式出现的自身肽段或“交叉反应性”外来(如病毒)肽段所诱导;一旦被激活,这些潜在的自身反应性T细胞可能会引发自身攻击性疾病(如糖尿病)。在RIP-GP转基因小鼠品系Bln中评估了针对此类T细胞介导的免疫病理疾病进行疫苗接种的可能性。任何用自身抗原本身进行疫苗接种的尝试(如表达LCMV-GP的重组痘苗病毒)都无法保护小鼠免受疾病侵害。然而,用表达LCMV核蛋白的重组痘苗病毒(疫苗-NP)作为非GP LCMV疫苗进行免疫能够调节免疫反应,并以MHC依赖的方式预防自身攻击性疾病。相比之下,在新生期诱导耐受,或者更普遍适用的是,通过致死性照射并用表达新自身抗原的骨髓细胞进行重建,在这种模型情况下总能预防病毒诱导的糖尿病。